Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Enzymatic Therapy Cell Forte

This article was originally published in The Tan Sheet

Executive Summary

Ad in June issue of Vegetarian Times proclaims the supplement "increases natural killer cell activity." The product contains inositol hexaphosphate, or IP-6. "Virtually all" cells "contain and require inositol hexaphosphate...for healthy function," the ad says, adding: "Unfortunately, it only takes one damaged cell to initiate serious health problems." Consumers "can dramatically increase...natural cellular defenses" by taking the product. Ads also are running in the May issues of Let's Live and Natural Foods Merchandiser, as well as July issues of Better Nutrition and Natural Health. Cell Forte was launched mid-March ("The Tan Sheet" March 9, p. 8). Materials from the patent holder for the use of inositol hexaphosphate, Abulkalam Shamsuddin, MD, PhD, University of Maryland, declare IP-6 has the "power to prevent & treat cancer"...
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS088342

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel